EARNINGS2020 Earnings Calendar: When Do Top Companies Report This Quarter?By Steve Fiorillo2 hours ago
JIM CRAMERHealthcare Innovation: Cramer's 'Mad Money' Recap (Monday 1/13/20)By Scott RuttJan 13, 2020 9:01 PM EST
JIM CRAMERToo Much Risk?: Cramer's 'Mad Money' Recap (Friday 1/10/20)By Scott RuttJan 10, 2020 8:38 PM EST
INVESTINGNektar Therapeutics, Bristol-Myers Expand Effort to Develop Treatment for CancerBy Dan WeilJan 10, 2020 1:01 PM EST
JIM CRAMERAll About Momentum: Cramer's 'Mad Money' Recap (Thursday 1/9/20)By Scott RuttJan 9, 2020 9:09 PM EST
INVESTINGBristol-Myers, Gilead, Biogen, Other Drugmakers Increased U.S. List Prices on Jan. 1: ReportBy Rob LenihanJan 2, 2020 1:41 PM EST
MARKETSTrump Impeachment, Dow Futures, Nike, Micron, Facebook - 5 Things You Must Know ThursdayBy Joseph WoelfelDec 19, 2019 10:04 AM EST
POLITICSPresident Donald J. Trump Impeached by House of RepresentativesBy Tom BemisDec 18, 2019 8:52 PM EST
JIM CRAMERWhy This Trade Deal Matters: Cramer's 'Mad Money' Recap (Monday 12/16/19)By Scott RuttDec 16, 2019 8:56 PM EST
INVESTINGBuy Bristol-Myers Squibb on a Dip for More Gains in 2020By Bret KenwellDec 16, 2019 2:15 PM EST
MARKETSS&P 500 Winners and Losers- Stocks Hit All-Time HighsBy Danny PetersonDec 14, 2019 2:16 PM EST
INVESTINGIf U.S. Interest Rates Turn Negative, Here's Where You Should InvestBy Jason OrestesDec 10, 2019 2:45 PM EST
INVESTINGBristol-Myers Jumps After Celgene-Acquired Cancer Treatment Shows PromiseBy Martin BaccardaxDec 9, 2019 2:02 PM EST
JIM CRAMERThis Market Makes Sense : Cramer's 'Mad Money' Recap (Monday 12/6/19)By Scott RuttDec 6, 2019 8:37 PM EST
STOCKSBristol-Myers Closes $74 Billion Celgene Takeover; Shares GainBy Martin BaccardaxNov 21, 2019 9:37 AM EST
INVESTINGBristol-Myers Squibb Slips on Poor Skin Cancer Trial ResultsBy M. Corey GoldmanNov 20, 2019 10:05 AM EST
MARKETSServiceNow Jumps as Stock Is Added to the S&P 500, Replacing CelgeneBy Joseph WoelfelNov 19, 2019 9:36 AM EST
